archive-com.com » COM » G » GLSV-VC.COM

Total: 39

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • GLSV - Global Life Science Ventures
    buy outs For this purpose GLSV provides finance advice and access to expertise and networks The group currently advises and manages funds totalling more than 200 million With offices in Germany and Switzerland GLSV acts as one team with a global perspective Profile Experience History Clear Focus Key Strengths Track Record Team Investment Practice Portfolio FAQ Download Area News Events Contact Us Home Sitemap Imprint Text size Expert Group The

    Original URL path: http://www.glsv-vc.com/profile/group.html (2016-04-25)
    Open archived version from archive


  • 7TM Pharma receives milestone payment from asthma and allergy collaboration
    7 transmembrane receptor Mette Kirstine Agger CEO of 7TM Pharma We are very pleased with the progression of this research collaboration in such an important therapeutic area of asthma and allergy The selection of this pre clinical candidate further demonstrates the value of our SD3 approach in various disease areas beyond our own focus area of metabolic disorders Asthma is a chronic disease characterized by recurrent attacks of breathlessness and wheezing and the disease is the most common chronic disease among children It currently affects 300 million people worldwide WHO Allergy occurs when the body has an abnormal reaction to an everyday substance allergen Allergy is one of the main causes for developing asthma and is often underestimated under diagnosed and under treated despite its high prevalence and effects on the quality of life Symptoms vary from mild to severe and even fatal 7TM Pharma Contact person Mette Kirstine Agger CEO Tel 45 39 25 77 77 Email About 7TM Pharma 7TM Pharma is a biotech company focusing on discovery and development of new drugs targeting 7TM receptors 7TM Pharma s primary therapeutic area is metabolic diseases including obesity Type 2 diabetes and cardiovascular diseases The basis for 7TM Pharma

    Original URL path: http://www.glsv-vc.com/downloads/news.htm?M=News&PID=42&NewsID=33 (2016-04-25)
    Open archived version from archive

  • CombinatoRx : Investor Relations : News Release
    amplifies mometasone s anti inflammatory activities without enhancing glucocorticoid side effects to provide a potent topical glucocorticoid with an improved therapeutic index We have developed a novel topical cream formulation of CRx 191 which provides the first topical formulation of nortriptyline We have demonstrated that the CRx 191 class of tricyclics and glucocorticoids are safe and effective in multiple experimental and preclinical models of inflammation CRx 191 is under development for psoriasis and other glucocorticoid responsive dermatoses In addition to this Phase 2a clinical trial for plaque psoriasis an earlier safety study conducted in healthy volunteers evaluated the tolerability of CRx 191 and its potential to induce skin thinning a key treatment limiting side effect of many potent glucocorticoids In this study the CRx 191 combination did not induce skin thinning above mometasone alone About the Trial Design This Phase 2a clinical trial was a 12 day single center randomized double blind placebo controlled study evaluating the efficacy safety and tolerability of CRx 191 in reducing psoriatic infiltrate band thickness extent of psoriatic inflammation in subjects with plaque psoriasis Twenty one subjects were enrolled with chronic stable plaque psoriasis with a single plaque covering an area sufficient for six treatment fields All subjects received all treatments under an occlusive dressing in the selected treatment area CRx 191 low dose 0 1 mometasone furoate 0 05 nortriptyline CRx 191 high dose 0 1 mometasone furoate 0 1 nortiptyline 0 1 mometasone alone 0 05 nortriptyline alone 0 1 nortriptyline alone and placebo Endpoints included reduction from baseline in psoriatic infiltrate thickness as measured by high frequency ultrasound erythema as measured by chromametry clinical skin condition score and histologic analysis of inflammatory biomarkers Statistical analysis for all endpoints was conducted by calculating the mean of the difference in change from baseline to day 12 between CRx 191 and each of its comparator arms Data provided are per protocol Infiltrate band thickness as measured by ultrasound is a well recognized method for clinical assessment of anti psoriatic action The clinical relevance of the test has been documented Wendt 1982 Gassmueller 1993 By using an occlusive dressing six test fields can be examined per subject allowing intra individual test site comparison with the goal of providing clinically meaningful results using a relatively small cohort of subjects About Psoriasis Psoriasis is a chronic inflammatory skin disease affecting between 6 and 7 5 million people in the United States characterized by skin thickening redness and scaling Dermatologists favor the use of local topical delivery in all but the most severe cases of psoriasis to limit systemic exposure and avoid systemic side effects Glucocorticoids are the most commonly prescribed class of topical treatment used in psoriasis Existing topical glucocorticoids are available in a wide range of potencies Currently available high potency topical glucocorticoids are associated with local skin toxicities including thinning following only short periods of exposure and irreversible skin atrophy after longer treatment periods A topical selective glucocorticoid amplifier that enhances potency without enhancing side effects

    Original URL path: http://www.glsv-vc.com/downloads/phoenix.htm?M=News&PID=42&NewsID=33 (2016-04-25)
    Open archived version from archive

  • Intercell
    seasonal Influenza vaccine formulated with IC31 completed successfully Intercell s adjuvant IC31 demonstrates very good safety and tolerability profile Novartis will continue clinical Phase I II development of IC31 adjuvanted flu vaccines in 2008 Joint therapeutic vaccine program against HCV met primary endpoints in Phase II data confirms findings of the interim analysis from Q3 2007 statistically significant viral load reduction and excellent safety profile further clinical trials in co development with Novartis to include IC31 Cooperation with Novartis is based on a major strategic partnership that was signed in July of 2007 HOSPITAL ACQUIRED INFECTIONS S aureus vaccine Merck Co Inc has initiated Phase II clinical development by the end of 2007 Intercell expects further extension of clinical program into additional indications in early 2008 Pseudomonas vaccine preparations for start of clinical Phase II III trials in 2008 underway Pre clinical candidates for further nosocomial vaccine and antibody product targets including Klebsiella have been identified TUBERCULOSIS Further clinical trials started at the Department of Infectious Diseases at the Leiden University Medical Center Netherlands within the new global franchise to fight Tuberculosis Tuberculosis vaccine will be further developed in a collaboration between Sanofi Pasteur and Statens Serum Institut SSI including Intercell s adjuvant IC31 strongly supported by the Aeras Global Tuberculosis Foundation and the EU TECHNOLOGY PLATFORMS IC31 AIP Pneumococcus vaccine candidate funded by PATH on course to entering clinical Phase I trials in 2008 Developmental programs and partnerships in the field of vaccines and monoclonal antibodies for Group B Streptococcus and hospital acquired infections to be accelerated New partnerships for adjuvant IC31 and the definition of new vaccine candidates from AIP expected for 2008 MANAGEMENT BOARD The Management Board with Gerd Zettlmeissl as Chief Executive Officer Werner Lanthaler as Chief Financial Officer and Alexander von Gabain as Chief Scientific

    Original URL path: http://www.glsv-vc.com/downloads/ShowArticle.htm?M=News&PID=42&NewsID=33 (2016-04-25)
    Open archived version from archive

  • GLSV - Biography of Frederick Frank
    million With offices in Germany and Switzerland GLSV acts as one team with a global perspective Profile Experience History Clear Focus Key Strengths Track Record Expert Group Team Investment Practice Portfolio FAQ Download Area News Events Contact Us Home Sitemap Imprint Text size Frederick Frank biography Fred Frank Vice Chairman and Director Lehman Brothers is a veteran and experienced specialist in investment banking services for companies in the pharmaceutical biotechnology

    Original URL path: http://www.glsv-vc.com/profile/frederick_frank.html (2016-04-25)
    Open archived version from archive

  • GLSV - Biography of Dr. Georges Haas
    manages funds totalling more than 200 million With offices in Germany and Switzerland GLSV acts as one team with a global perspective Profile Experience History Clear Focus Key Strengths Track Record Expert Group Team Investment Practice Portfolio FAQ Download Area News Events Contact Us Home Sitemap Imprint Text size Dr Georges Haas biography Dr Georges Haas has a highly successful record of R D management throughout his career with the

    Original URL path: http://www.glsv-vc.com/profile/georges-haas.html (2016-04-25)
    Open archived version from archive

  • GLSV - Biography of ir John James Skehe
    than 200 million With offices in Germany and Switzerland GLSV acts as one team with a global perspective Profile Experience History Clear Focus Key Strengths Track Record Expert Group Team Investment Practice Portfolio FAQ Download Area News Events Contact Us Home Sitemap Imprint Text size Sir John James Skehel biography Sir John James Skehel is the Director of the MRC National Institute for Medical Research in London He has been

    Original URL path: http://www.glsv-vc.com/profile/john-james-skehel.html (2016-04-25)
    Open archived version from archive



  •